{"transactions":[{"id":1083936,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":77330,"kind":"person","name":"Goldberg Mark Alan","position":1,"cik":"0001532475","reported_name":"Goldberg Mark Alan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-21T19:46:05.000Z","date":"2025-07-17","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":4570,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") by and among the Issuer, SANOFI, a French societe anonyme (\"Parent\"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent (\"Aventis\"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis (\"Purchaser\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the \"Common Stock\"), for (i) $129.00 per share, without interest (the \"Cash Offer Price\"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a \"CVR\" and together with the Cash Offer Price, the \"Offer Consideration\"). On July 17, 2025 (the \"Effective Time\"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."}],"balance_after":0,"derivative":{"exercise_price":106.14,"underlying":"Common Stock","underlying_shares":4570},"source":{"system":"sec-edgar","filing":"0001104659-25-069384","document":"tm2521348-8_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1532475/000110465925069384/tm2521348-8_4seq1.xml","form_type":"4"}},{"id":1083935,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":77330,"kind":"person","name":"Goldberg Mark Alan","position":1,"cik":"0001532475","reported_name":"Goldberg Mark Alan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-21T19:46:05.000Z","date":"2025-07-17","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":5300,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") by and among the Issuer, SANOFI, a French societe anonyme (\"Parent\"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent (\"Aventis\"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis (\"Purchaser\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the \"Common Stock\"), for (i) $129.00 per share, without interest (the \"Cash Offer Price\"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a \"CVR\" and together with the Cash Offer Price, the \"Offer Consideration\"). On July 17, 2025 (the \"Effective Time\"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."}],"balance_after":0,"derivative":{"exercise_price":63.66,"underlying":"Common Stock","underlying_shares":5300},"source":{"system":"sec-edgar","filing":"0001104659-25-069384","document":"tm2521348-8_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1532475/000110465925069384/tm2521348-8_4seq1.xml","form_type":"4"}},{"id":1083934,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":77330,"kind":"person","name":"Goldberg Mark Alan","position":1,"cik":"0001532475","reported_name":"Goldberg Mark Alan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-21T19:46:05.000Z","date":"2025-07-17","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":5300,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") by and among the Issuer, SANOFI, a French societe anonyme (\"Parent\"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent (\"Aventis\"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis (\"Purchaser\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the \"Common Stock\"), for (i) $129.00 per share, without interest (the \"Cash Offer Price\"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a \"CVR\" and together with the Cash Offer Price, the \"Offer Consideration\"). On July 17, 2025 (the \"Effective Time\"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."}],"balance_after":0,"derivative":{"exercise_price":50.64,"underlying":"Common Stock","underlying_shares":5300},"source":{"system":"sec-edgar","filing":"0001104659-25-069384","document":"tm2521348-8_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1532475/000110465925069384/tm2521348-8_4seq1.xml","form_type":"4"}},{"id":1083933,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":77330,"kind":"person","name":"Goldberg Mark Alan","position":1,"cik":"0001532475","reported_name":"Goldberg Mark Alan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-21T19:46:05.000Z","date":"2025-07-17","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":4500,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") by and among the Issuer, SANOFI, a French societe anonyme (\"Parent\"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent (\"Aventis\"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis (\"Purchaser\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the \"Common Stock\"), for (i) $129.00 per share, without interest (the \"Cash Offer Price\"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a \"CVR\" and together with the Cash Offer Price, the \"Offer Consideration\"). On July 17, 2025 (the \"Effective Time\"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."}],"balance_after":0,"derivative":{"exercise_price":87.13,"underlying":"Common Stock","underlying_shares":4500},"source":{"system":"sec-edgar","filing":"0001104659-25-069384","document":"tm2521348-8_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1532475/000110465925069384/tm2521348-8_4seq1.xml","form_type":"4"}},{"id":1083932,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":77330,"kind":"person","name":"Goldberg Mark Alan","position":1,"cik":"0001532475","reported_name":"Goldberg Mark Alan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-21T19:46:05.000Z","date":"2025-07-17","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":4500,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") by and among the Issuer, SANOFI, a French societe anonyme (\"Parent\"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent (\"Aventis\"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis (\"Purchaser\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the \"Common Stock\"), for (i) $129.00 per share, without interest (the \"Cash Offer Price\"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a \"CVR\" and together with the Cash Offer Price, the \"Offer Consideration\"). On July 17, 2025 (the \"Effective Time\"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."}],"balance_after":0,"derivative":{"exercise_price":76.24,"underlying":"Common Stock","underlying_shares":4500},"source":{"system":"sec-edgar","filing":"0001104659-25-069384","document":"tm2521348-8_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1532475/000110465925069384/tm2521348-8_4seq1.xml","form_type":"4"}},{"id":1083931,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":77330,"kind":"person","name":"Goldberg Mark Alan","position":1,"cik":"0001532475","reported_name":"Goldberg Mark Alan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-21T19:46:05.000Z","date":"2025-07-17","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":4875,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") by and among the Issuer, SANOFI, a French societe anonyme (\"Parent\"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent (\"Aventis\"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis (\"Purchaser\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the \"Common Stock\"), for (i) $129.00 per share, without interest (the \"Cash Offer Price\"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a \"CVR\" and together with the Cash Offer Price, the \"Offer Consideration\"). On July 17, 2025 (the \"Effective Time\"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."}],"balance_after":0,"derivative":{"exercise_price":96.77,"underlying":"Common Stock","underlying_shares":4875},"source":{"system":"sec-edgar","filing":"0001104659-25-069384","document":"tm2521348-8_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1532475/000110465925069384/tm2521348-8_4seq1.xml","form_type":"4"}},{"id":1083930,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":77330,"kind":"person","name":"Goldberg Mark Alan","position":1,"cik":"0001532475","reported_name":"Goldberg Mark Alan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-21T19:46:05.000Z","date":"2025-07-17","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":7500,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") by and among the Issuer, SANOFI, a French societe anonyme (\"Parent\"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent (\"Aventis\"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis (\"Purchaser\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the \"Common Stock\"), for (i) $129.00 per share, without interest (the \"Cash Offer Price\"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a \"CVR\" and together with the Cash Offer Price, the \"Offer Consideration\"). On July 17, 2025 (the \"Effective Time\"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."}],"balance_after":0,"derivative":{"exercise_price":69.79,"underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001104659-25-069384","document":"tm2521348-8_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1532475/000110465925069384/tm2521348-8_4seq1.xml","form_type":"4"}},{"id":1083929,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":77330,"kind":"person","name":"Goldberg Mark Alan","position":1,"cik":"0001532475","reported_name":"Goldberg Mark Alan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-21T19:46:05.000Z","date":"2025-07-17","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":10909,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") by and among the Issuer, SANOFI, a French societe anonyme (\"Parent\"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent (\"Aventis\"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis (\"Purchaser\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the \"Common Stock\"), for (i) $129.00 per share, without interest (the \"Cash Offer Price\"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a \"CVR\" and together with the Cash Offer Price, the \"Offer Consideration\"). On July 17, 2025 (the \"Effective Time\"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."}],"balance_after":0,"derivative":{"exercise_price":46.02,"underlying":"Common Stock","underlying_shares":10909},"source":{"system":"sec-edgar","filing":"0001104659-25-069384","document":"tm2521348-8_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1532475/000110465925069384/tm2521348-8_4seq1.xml","form_type":"4"}},{"id":1083928,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":77330,"kind":"person","name":"Goldberg Mark Alan","position":1,"cik":"0001532475","reported_name":"Goldberg Mark Alan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-07-21T19:46:05.000Z","date":"2025-07-17","kind":"other","planned":false,"acquired":false,"shares":18254,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") by and among the Issuer, SANOFI, a French societe anonyme (\"Parent\"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent (\"Aventis\"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis (\"Purchaser\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the \"Common Stock\"), for (i) $129.00 per share, without interest (the \"Cash Offer Price\"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a \"CVR\" and together with the Cash Offer Price, the \"Offer Consideration\"). On July 17, 2025 (the \"Effective Time\"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each share of Common Stock held by the Reporting Person was tendered in exchange for the Offer Consideration."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-25-069384","document":"tm2521348-8_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1532475/000110465925069384/tm2521348-8_4seq1.xml","form_type":"4"}},{"id":1083927,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":77330,"kind":"person","name":"Goldberg Mark Alan","position":1,"cik":"0001532475","reported_name":"Goldberg Mark Alan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-07-21T19:46:05.000Z","date":"2025-07-17","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":3902,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") by and among the Issuer, SANOFI, a French societe anonyme (\"Parent\"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent (\"Aventis\"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis (\"Purchaser\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the \"Common Stock\"), for (i) $129.00 per share, without interest (the \"Cash Offer Price\"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a \"CVR\" and together with the Cash Offer Price, the \"Offer Consideration\"). On July 17, 2025 (the \"Effective Time\"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding restricted stock unit (\"RSU\"), whether vested or unvested, was cancelled and automatically converted into the right to receive the Offer Consideration."}],"balance_after":18254,"source":{"system":"sec-edgar","filing":"0001104659-25-069384","document":"tm2521348-8_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1532475/000110465925069384/tm2521348-8_4seq1.xml","form_type":"4"}},{"id":1102430,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":77330,"kind":"person","name":"Goldberg Mark Alan","position":1,"cik":"0001532475","reported_name":"Goldberg Mark Alan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-24T16:26:49.000Z","date":"2025-06-18","kind":"grant","planned":false,"acquired":true,"shares":3902,"price":128.12,"value":499924.24,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported transaction involved the Reporting Person's receipt of a grant of restricted stock units. The restricted stock units vest with respect to 100% of the shares underlying the restricted stock units on the earlier of (i) June 18, 2026 and (ii) the next annual meeting of the Issuer's stockholders. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock."}],"balance_after":22156,"source":{"system":"sec-edgar","filing":"0001415889-25-018084","document":"form4-06242025_080645.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1532475/000141588925018084/form4-06242025_080645.xml","form_type":"4"}},{"id":1478580,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":77330,"kind":"person","name":"Goldberg Mark Alan","position":1,"cik":"0001532475","reported_name":"Goldberg Mark Alan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-14T17:34:16.000Z","date":"2024-06-12","kind":"grant","planned":false,"acquired":true,"shares":4570,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option vests with respect to 100% of the shares underlying the option on the earlier of (i) June 12, 2025 and (ii) the next annual meeting of the Issuer's stockholders."}],"balance_after":4570,"derivative":{"exercise_price":106.14,"expiration_date":"2034-06-12","underlying":"Common Stock","underlying_shares":4570},"source":{"system":"sec-edgar","filing":"0001415889-24-016981","document":"form4-06142024_090611.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1532475/000141588924016981/form4-06142024_090611.xml","form_type":"4"}},{"id":1478579,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":77330,"kind":"person","name":"Goldberg Mark Alan","position":1,"cik":"0001532475","reported_name":"Goldberg Mark Alan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-14T17:34:16.000Z","date":"2024-06-12","kind":"grant","planned":false,"acquired":true,"shares":2242,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction involved the Reporting Person's receipt of a grant of restricted stock units. The restricted stock units vest with respect to 100% of the shares underlying the restricted stock units on the earlier of (i) June 12, 2025 and (ii) the next annual meeting of the Issuer's stockholders. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock."}],"balance_after":18254,"source":{"system":"sec-edgar","filing":"0001415889-24-016981","document":"form4-06142024_090611.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1532475/000141588924016981/form4-06142024_090611.xml","form_type":"4"}},{"id":1531811,"issuer":{"id":5255,"kind":"organization","name":"CRESCENT BIOPHARMA, INC.","symbol":"CBIO"},"owners":[{"id":77330,"kind":"person","name":"Goldberg Mark Alan","position":1,"cik":"0001532475","reported_name":"Goldberg Mark Alan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-05-01T20:30:04.000Z","date":"2024-05-01","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option vest on May 1, 2025, subject to the reporting person's continuous service as of such vesting date."}],"balance_after":40000,"derivative":{"exercise_price":1.62,"expiration_date":"2034-04-30","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001415889-24-011869","document":"form4-05012024_080555.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1253689/000141588924011869/form4-05012024_080555.xml","form_type":"4"}},{"id":1552981,"issuer":{"id":5255,"kind":"organization","name":"CRESCENT BIOPHARMA, INC.","symbol":"CBIO"},"owners":[{"id":77330,"kind":"person","name":"Goldberg Mark Alan","position":1,"cik":"0001532475","reported_name":"Goldberg Mark Alan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-04-02T20:05:22.000Z","date":"2024-03-29","kind":"grant","planned":false,"acquired":true,"shares":4584,"price":3,"value":13752.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares will be issued to the reporting person pursuant to the issuer's non-employee director compensation policy in lieu of board and committee retainer fees of $13,750."}],"balance_after":24828,"source":{"system":"sec-edgar","filing":"0001415889-24-009744","document":"form4-04022024_040413.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1253689/000141588924009744/form4-04022024_040413.xml","form_type":"4"}},{"id":1650435,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":77330,"kind":"person","name":"Goldberg Mark Alan","position":1,"cik":"0001532475","reported_name":"Goldberg Mark Alan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-12T16:42:43.000Z","date":"2024-02-12","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":19597,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock (\"Stock Option\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock (\"Stock Option\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock (\"Stock Option\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option."}],"balance_after":0,"derivative":{"exercise_price":17.72,"expiration_date":"2033-06-14","underlying":"Common Stock","underlying_shares":19597},"source":{"system":"sec-edgar","filing":"0001104659-24-014708","document":"tm245865-9_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/855654/000110465924014708/tm245865-9_4seq1.xml","form_type":"4"}},{"id":1650434,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":77330,"kind":"person","name":"Goldberg Mark Alan","position":1,"cik":"0001532475","reported_name":"Goldberg Mark Alan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-12T16:42:43.000Z","date":"2024-02-12","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":44000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock (\"Stock Option\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock (\"Stock Option\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock (\"Stock Option\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option."}],"balance_after":0,"derivative":{"exercise_price":3.37,"expiration_date":"2032-06-15","underlying":"Common Stock","underlying_shares":44000},"source":{"system":"sec-edgar","filing":"0001104659-24-014708","document":"tm245865-9_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/855654/000110465924014708/tm245865-9_4seq1.xml","form_type":"4"}},{"id":1650433,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":77330,"kind":"person","name":"Goldberg Mark Alan","position":1,"cik":"0001532475","reported_name":"Goldberg Mark Alan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-12T16:42:43.000Z","date":"2024-02-12","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":44000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock (\"Stock Option\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock (\"Stock Option\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock (\"Stock Option\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option."}],"balance_after":0,"derivative":{"exercise_price":6.77,"expiration_date":"2031-06-16","underlying":"Common Stock","underlying_shares":44000},"source":{"system":"sec-edgar","filing":"0001104659-24-014708","document":"tm245865-9_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/855654/000110465924014708/tm245865-9_4seq1.xml","form_type":"4"}},{"id":1650432,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":77330,"kind":"person","name":"Goldberg Mark Alan","position":1,"cik":"0001532475","reported_name":"Goldberg Mark Alan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-12T16:42:43.000Z","date":"2024-02-12","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":50000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock (\"Stock Option\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock (\"Stock Option\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock (\"Stock Option\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option."}],"balance_after":0,"derivative":{"exercise_price":4.56,"expiration_date":"2030-06-17","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001104659-24-014708","document":"tm245865-9_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/855654/000110465924014708/tm245865-9_4seq1.xml","form_type":"4"}},{"id":1650431,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":77330,"kind":"person","name":"Goldberg Mark Alan","position":1,"cik":"0001532475","reported_name":"Goldberg Mark Alan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-12T16:42:43.000Z","date":"2024-02-12","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":18000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock (\"Stock Option\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock (\"Stock Option\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock (\"Stock Option\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option."}],"balance_after":0,"derivative":{"exercise_price":2.1,"expiration_date":"2029-06-20","underlying":"Common Stock","underlying_shares":18000},"source":{"system":"sec-edgar","filing":"0001104659-24-014708","document":"tm245865-9_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/855654/000110465924014708/tm245865-9_4seq1.xml","form_type":"4"}},{"id":1650430,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":77330,"kind":"person","name":"Goldberg Mark Alan","position":1,"cik":"0001532475","reported_name":"Goldberg Mark Alan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-12T16:42:43.000Z","date":"2024-02-12","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":18000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock (\"Stock Option\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock (\"Stock Option\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock (\"Stock Option\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option."}],"balance_after":0,"derivative":{"exercise_price":11.21,"expiration_date":"2028-06-20","underlying":"Common Stock","underlying_shares":18000},"source":{"system":"sec-edgar","filing":"0001104659-24-014708","document":"tm245865-9_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/855654/000110465924014708/tm245865-9_4seq1.xml","form_type":"4"}},{"id":1650429,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":77330,"kind":"person","name":"Goldberg Mark Alan","position":1,"cik":"0001532475","reported_name":"Goldberg Mark Alan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-12T16:42:43.000Z","date":"2024-02-12","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":10000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock (\"Stock Option\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock (\"Stock Option\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock (\"Stock Option\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option."}],"balance_after":0,"derivative":{"exercise_price":4.64,"expiration_date":"2027-06-13","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001104659-24-014708","document":"tm245865-9_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/855654/000110465924014708/tm245865-9_4seq1.xml","form_type":"4"}},{"id":1650428,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":77330,"kind":"person","name":"Goldberg Mark Alan","position":1,"cik":"0001532475","reported_name":"Goldberg Mark Alan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-12T16:42:43.000Z","date":"2024-02-12","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":5000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock (\"Stock Option\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock (\"Stock Option\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock (\"Stock Option\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option."}],"balance_after":0,"derivative":{"exercise_price":1.84,"expiration_date":"2026-12-09","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001104659-24-014708","document":"tm245865-9_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/855654/000110465924014708/tm245865-9_4seq1.xml","form_type":"4"}},{"id":1650427,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":77330,"kind":"person","name":"Goldberg Mark Alan","position":1,"cik":"0001532475","reported_name":"Goldberg Mark Alan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-12T16:42:43.000Z","date":"2024-02-12","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":10000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock (\"Stock Option\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock (\"Stock Option\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock (\"Stock Option\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option."}],"balance_after":0,"derivative":{"exercise_price":13.07,"expiration_date":"2025-11-10","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001104659-24-014708","document":"tm245865-9_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/855654/000110465924014708/tm245865-9_4seq1.xml","form_type":"4"}},{"id":1650426,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":77330,"kind":"person","name":"Goldberg Mark Alan","position":1,"cik":"0001532475","reported_name":"Goldberg Mark Alan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-12T16:42:43.000Z","date":"2024-02-12","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":10000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock (\"Stock Option\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock (\"Stock Option\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock (\"Stock Option\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option."}],"balance_after":0,"derivative":{"exercise_price":10.1,"expiration_date":"2024-11-11","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001104659-24-014708","document":"tm245865-9_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/855654/000110465924014708/tm245865-9_4seq1.xml","form_type":"4"}},{"id":1650425,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":77330,"kind":"person","name":"Goldberg Mark Alan","position":1,"cik":"0001532475","reported_name":"Goldberg Mark Alan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Deferred Share Unit","published_at":"2024-02-12T16:42:43.000Z","date":"2024-02-12","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":160350,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each deferred share unit (\"DSU\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such DSU, an amount in cash (less any applicable withholding taxes) equal to (i) the number of shares of Common Stock subject to such DSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each deferred share unit (\"DSU\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such DSU, an amount in cash (less any applicable withholding taxes) equal to (i) the number of shares of Common Stock subject to such DSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each deferred share unit (\"DSU\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such DSU, an amount in cash (less any applicable withholding taxes) equal to (i) the number of shares of Common Stock subject to such DSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each deferred share unit (\"DSU\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such DSU, an amount in cash (less any applicable withholding taxes) equal to (i) the number of shares of Common Stock subject to such DSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":160350},"source":{"system":"sec-edgar","filing":"0001104659-24-014708","document":"tm245865-9_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/855654/000110465924014708/tm245865-9_4seq1.xml","form_type":"4"}},{"id":1650424,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":77330,"kind":"person","name":"Goldberg Mark Alan","position":1,"cik":"0001532475","reported_name":"Goldberg Mark Alan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2024-02-12T16:42:43.000Z","date":"2024-02-12","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":13090,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit (\"RSU\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such RSU, an amount in cash (less any applicable withholding taxes) equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit (\"RSU\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such RSU, an amount in cash (less any applicable withholding taxes) equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit (\"RSU\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such RSU, an amount in cash (less any applicable withholding taxes) equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit (\"RSU\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such RSU, an amount in cash (less any applicable withholding taxes) equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":13090},"source":{"system":"sec-edgar","filing":"0001104659-24-014708","document":"tm245865-9_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/855654/000110465924014708/tm245865-9_4seq1.xml","form_type":"4"}},{"id":1650423,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":77330,"kind":"person","name":"Goldberg Mark Alan","position":1,"cik":"0001532475","reported_name":"Goldberg Mark Alan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-02-12T16:42:43.000Z","date":"2024-02-12","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":60720,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated November 30, 2023, by and among the Issuer, AbbVie Inc., a Delaware corporation (\"AbbVie\"), Athene Subsidiary LLC, a Delaware limited liability company and wholly owned subsidiary of AbbVie (\"Intermediate Sub\"), and Athene Merger Sub Inc., a Massachusetts corporation and wholly owned subsidiary of Intermediate Sub (\"Purchaser\"), pursuant to which Purchaser merged with and into the Issuer with the Issuer continuing as the surviving corporation (the \"Merger\"). At the effective time of the Merger (the \"Effective Time\"), each share of common stock, par value $.01 per share, of the Issuer (the \"Common Stock\"), that was issued and outstanding immediately prior to the Effective Time was converted into the right to receive an amount in cash equal to $31.26, without interest (the \"Merger Consideration\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated November 30, 2023, by and among the Issuer, AbbVie Inc., a Delaware corporation (\"AbbVie\"), Athene Subsidiary LLC, a Delaware limited liability company and wholly owned subsidiary of AbbVie (\"Intermediate Sub\"), and Athene Merger Sub Inc., a Massachusetts corporation and wholly owned subsidiary of Intermediate Sub (\"Purchaser\"), pursuant to which Purchaser merged with and into the Issuer with the Issuer continuing as the surviving corporation (the \"Merger\"). At the effective time of the Merger (the \"Effective Time\"), each share of common stock, par value $.01 per share, of the Issuer (the \"Common Stock\"), that was issued and outstanding immediately prior to the Effective Time was converted into the right to receive an amount in cash equal to $31.26, without interest (the \"Merger Consideration\")."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-24-014708","document":"tm245865-9_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/855654/000110465924014708/tm245865-9_4seq1.xml","form_type":"4"}},{"id":1694992,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":77330,"kind":"person","name":"Goldberg Mark Alan","position":1,"cik":"0001532475","reported_name":"Goldberg Mark Alan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-01-03T17:45:12.000Z","date":"2023-12-29","kind":"grant","planned":false,"acquired":true,"shares":569,"price":29.65,"value":16870.85,"ownership":{"direct":true},"footnotes":[{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F1","text":"Shares of common stock issued pursuant to the Compensation Policy for Non-Employee Directors as amended June 14, 2023 in lieu of cash compensation for services performed for the quarter ended December 31, 2023."}],"balance_after":60720,"source":{"system":"sec-edgar","filing":"0001415889-24-000376","document":"form4-01032024_100102.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/855654/000141588924000376/form4-01032024_100102.xml","form_type":"4"}},{"id":1696207,"issuer":{"id":5255,"kind":"organization","name":"CRESCENT BIOPHARMA, INC.","symbol":"CBIO"},"owners":[{"id":77330,"kind":"person","name":"Goldberg Mark Alan","position":1,"cik":"0001532475","reported_name":"Goldberg Mark Alan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common stock","published_at":"2024-01-02T21:05:19.000Z","date":"2023-12-29","kind":"grant","planned":false,"acquired":true,"shares":5827,"price":2.36,"value":13751.72,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares were issued to the reporting person pursuant to the issuer's non-employee director compensation policy in lieu of board and committee retainer fees of $13,750."}],"balance_after":20244,"source":{"system":"sec-edgar","filing":"0001209191-24-000067","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1253689/000120919124000067/doc4.xml","form_type":"4"}},{"id":1752825,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":77330,"kind":"person","name":"Goldberg Mark Alan","position":1,"cik":"0001532475","reported_name":"Goldberg Mark Alan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-11-01T17:59:27.000Z","date":"2023-10-30","kind":"exercise","planned":true,"acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effected pursuant to a trading plan adopted on June 9, 2023 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option was granted on 11/12/2013 and is fully vested as of the transaction date."}],"balance_after":0,"derivative":{"exercise_price":14.7,"expiration_date":"2023-11-12","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001415889-23-014675","document":"form4-11012023_091121.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/855654/000141588923014675/form4-11012023_091121.xml","form_type":"4"}},{"id":1752824,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":77330,"kind":"person","name":"Goldberg Mark Alan","position":1,"cik":"0001532475","reported_name":"Goldberg Mark Alan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-11-01T17:59:27.000Z","date":"2023-10-30","kind":"exercise","planned":true,"acquired":false,"shares":10000,"price":15.08,"value":150800.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effected pursuant to a trading plan adopted on June 9, 2023 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.90 to $15.20, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within these ranges."}],"balance_after":60151,"source":{"system":"sec-edgar","filing":"0001415889-23-014675","document":"form4-11012023_091121.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/855654/000141588923014675/form4-11012023_091121.xml","form_type":"4"}},{"id":1752823,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":77330,"kind":"person","name":"Goldberg Mark Alan","position":1,"cik":"0001532475","reported_name":"Goldberg Mark Alan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-11-01T17:59:27.000Z","date":"2023-10-30","kind":"exercise","planned":true,"acquired":true,"shares":10000,"price":14.7,"value":147000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effected pursuant to a trading plan adopted on June 9, 2023 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."}],"balance_after":70151,"source":{"system":"sec-edgar","filing":"0001415889-23-014675","document":"form4-11012023_091121.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/855654/000141588923014675/form4-11012023_091121.xml","form_type":"4"}},{"id":1766847,"issuer":{"id":5255,"kind":"organization","name":"CRESCENT BIOPHARMA, INC.","symbol":"CBIO"},"owners":[{"id":77330,"kind":"person","name":"Goldberg Mark Alan","position":1,"cik":"0001532475","reported_name":"Goldberg Mark Alan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common stock","published_at":"2023-10-03T20:15:43.000Z","date":"2023-09-30","kind":"grant","planned":false,"acquired":true,"shares":9167,"price":1.5,"value":13750.5,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares were issued to the reporting person pursuant to the issuer's non-employee director compensation policy in lieu of board and committee retainer fees of $13,750."}],"balance_after":14417,"source":{"system":"sec-edgar","filing":"0001209191-23-051449","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1253689/000120919123051449/doc4.xml","form_type":"4"}},{"id":1771037,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":77330,"kind":"person","name":"Goldberg Mark Alan","position":1,"cik":"0001532475","reported_name":"Goldberg Mark Alan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-10-02T17:05:25.000Z","date":"2023-09-29","kind":"grant","planned":false,"acquired":true,"shares":1063,"price":15.87,"value":16869.81,"ownership":{"direct":true},"footnotes":[{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F1","text":"Shares of common stock issued pursuant to the Compensation Policy for Non-Employee Directors as amended June 14, 2023 in lieu of cash compensation for services performed for the quarter ended September 30, 2023."}],"balance_after":60151,"source":{"system":"sec-edgar","filing":"0001415889-23-013757","document":"form4-10022023_091013.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/855654/000141588923013757/form4-10022023_091013.xml","form_type":"4"}},{"id":1838226,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":77330,"kind":"person","name":"Goldberg Mark Alan","position":1,"cik":"0001532475","reported_name":"Goldberg Mark Alan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-07-05T17:53:38.000Z","date":"2023-06-30","kind":"grant","planned":false,"acquired":true,"shares":894,"price":18.87,"value":16869.78,"ownership":{"direct":true},"footnotes":[{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F1","text":"Shares of common stock issued pursuant to the Compensation Policy for Non-Employee Directors as amended June 14, 2023 for services performed for the quarter ended June 30, 2023."}],"balance_after":59088,"source":{"system":"sec-edgar","filing":"0001415889-23-010821","document":"form4-07052023_090734.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/855654/000141588923010821/form4-07052023_090734.xml","form_type":"4"}},{"id":1844905,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":77330,"kind":"person","name":"Goldberg Mark Alan","position":1,"cik":"0001532475","reported_name":"Goldberg Mark Alan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-23T19:06:48.000Z","date":"2023-06-21","kind":"grant","planned":false,"acquired":true,"shares":5300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option vests with respect to 100% of the shares underlying the option on the earlier of (i) June 21, 2024 and (ii) the next annual meeting of the Issuer's stockholders."}],"balance_after":5300,"derivative":{"exercise_price":63.66,"expiration_date":"2033-06-21","underlying":"Common Stock","underlying_shares":5300},"source":{"system":"sec-edgar","filing":"0001415889-23-010263","document":"form4-06232023_110645.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1532475/000141588923010263/form4-06232023_110645.xml","form_type":"4"}},{"id":1844904,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":77330,"kind":"person","name":"Goldberg Mark Alan","position":1,"cik":"0001532475","reported_name":"Goldberg Mark Alan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-23T19:06:48.000Z","date":"2023-06-21","kind":"grant","planned":false,"acquired":true,"shares":2600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction involved the Reporting Person's receipt of a grant of restricted stock units. The restricted stock units vest with respect to 100% of the shares underlying the restricted stock units on the earlier of (i) the next annual meeting of the Issuer's stockholders and (ii) June 21, 2024. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock."}],"balance_after":16012,"source":{"system":"sec-edgar","filing":"0001415889-23-010263","document":"form4-06232023_110645.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1532475/000141588923010263/form4-06232023_110645.xml","form_type":"4"}},{"id":1853408,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":77330,"kind":"person","name":"Goldberg Mark Alan","position":1,"cik":"0001532475","reported_name":"Goldberg Mark Alan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-16T16:45:03.000Z","date":"2023-06-14","kind":"grant","planned":false,"acquired":true,"shares":19597,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The stock options were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors, as amended, and the 2018 Employee, Director and Consultant Equity Incentive Plan, as amended."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The stock options vest ratably on each of 9/1/23, 12/1/23, 3/1/24, and 6/1/24, contingent upon the individual remaining a director as of each vesting date."}],"balance_after":19597,"derivative":{"exercise_price":17.72,"expiration_date":"2033-06-14","underlying":"Common Stock","underlying_shares":19597},"source":{"system":"sec-edgar","filing":"0001415889-23-009947","document":"form4-06162023_080600.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/855654/000141588923009947/form4-06162023_080600.xml","form_type":"4"}},{"id":1853407,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":77330,"kind":"person","name":"Goldberg Mark Alan","position":1,"cik":"0001532475","reported_name":"Goldberg Mark Alan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2023-06-16T16:45:03.000Z","date":"2023-06-14","kind":"grant","planned":false,"acquired":true,"shares":13090,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The restricted stock units (\"RSUs\") were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors, as amended, and the 2018 Employee, Director and Consultant Equity Incentive Plan, as amended. Each RSU represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The restricted stock units (\"RSUs\") were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors, as amended, and the 2018 Employee, Director and Consultant Equity Incentive Plan, as amended. Each RSU represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units vest on the one-year anniversary of the date of grant, contingent upon the individual remaining a director as of the vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units vest on the one-year anniversary of the date of grant, contingent upon the individual remaining a director as of the vesting date."}],"balance_after":13090,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":13090},"source":{"system":"sec-edgar","filing":"0001415889-23-009947","document":"form4-06162023_080600.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/855654/000141588923009947/form4-06162023_080600.xml","form_type":"4"}},{"id":1882303,"issuer":{"id":5255,"kind":"organization","name":"CRESCENT BIOPHARMA, INC.","symbol":"CBIO"},"owners":[{"id":77330,"kind":"person","name":"Goldberg Mark Alan","position":1,"cik":"0001532475","reported_name":"Goldberg Mark Alan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-05-22T20:23:11.000Z","date":"2023-05-19","kind":"grant","planned":false,"acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option vest on May 19, 2024, subject to the reporting person's continuous service as of such vesting date."}],"balance_after":35000,"derivative":{"exercise_price":1.98,"expiration_date":"2033-05-18","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001209191-23-031454","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1253689/000120919123031454/doc4.xml","form_type":"4"}},{"id":1930595,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":77330,"kind":"person","name":"Goldberg Mark Alan","position":1,"cik":"0001532475","reported_name":"Goldberg Mark Alan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-04-04T16:51:14.000Z","date":"2023-03-31","kind":"grant","planned":false,"acquired":true,"shares":4394,"price":3.84,"value":16872.96,"ownership":{"direct":true},"footnotes":[{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F1","text":"Shares of common stock issued pursuant to the Compensation Policy for Non-Employee Directors as amended December 15, 2022 for services performed for the quarter ended March 31, 2023."}],"balance_after":58194,"source":{"system":"sec-edgar","filing":"0001415889-23-006057","document":"form4-04042023_080405.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/855654/000141588923006057/form4-04042023_080405.xml","form_type":"4"}},{"id":2070649,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":77330,"kind":"person","name":"Goldberg Mark Alan","position":1,"cik":"0001532475","reported_name":"Goldberg Mark Alan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Deferred Share Unit","published_at":"2023-01-04T16:22:55.000Z","date":"2022-12-30","kind":"grant","acquired":true,"shares":3402,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The deferred share units vest upon issuance."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors."}],"balance_after":160350,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":3402},"source":{"system":"sec-edgar","filing":"0001415889-23-000304","document":"form4-01042023_090142.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/855654/000141588923000304/form4-01042023_090142.xml","form_type":"4"}},{"id":2146110,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":77330,"kind":"person","name":"Goldberg Mark Alan","position":1,"cik":"0001532475","reported_name":"Goldberg Mark Alan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Deferred Share Unit","published_at":"2022-10-04T16:14:04.000Z","date":"2022-09-30","kind":"grant","acquired":true,"shares":3530,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The deferred share units vest upon issuance."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors."}],"balance_after":156948,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":3530},"source":{"system":"sec-edgar","filing":"0001415889-22-010221","document":"form4-10042022_011048.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/855654/000141588922010221/form4-10042022_011048.xml","form_type":"4"}},{"id":2215878,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":77330,"kind":"person","name":"Goldberg Mark Alan","position":1,"cik":"0001532475","reported_name":"Goldberg Mark Alan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Deferred Share Unit","published_at":"2022-07-05T16:36:07.000Z","date":"2022-06-30","kind":"grant","acquired":true,"shares":3750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The deferred share units vest upon issuance."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors."}],"balance_after":153418,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":3750},"source":{"system":"sec-edgar","filing":"0001415889-22-007344","document":"form4-07052022_010743.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/855654/000141588922007344/form4-07052022_010743.xml","form_type":"4"}},{"id":2218524,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":77330,"kind":"person","name":"Goldberg Mark Alan","position":1,"cik":"0001532475","reported_name":"Goldberg Mark Alan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-30T21:55:37.000Z","date":"2022-06-21","kind":"grant","acquired":true,"shares":5300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option vests with respect to 100% of the shares underlying the option on the earlier of (i) June 21, 2023 and (ii) the next annual meeting of the Issuer's stockholders."}],"balance_after":5300,"derivative":{"exercise_price":50.64,"expiration_date":"2032-06-21","underlying":"Common Stock","underlying_shares":5300},"source":{"system":"sec-edgar","filing":"0001415889-22-007131","document":"form4-06302022_060625.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1532475/000141588922007131/form4-06302022_060625.xml","form_type":"4"}},{"id":2218523,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":77330,"kind":"person","name":"Goldberg Mark Alan","position":1,"cik":"0001532475","reported_name":"Goldberg Mark Alan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-06-30T21:55:37.000Z","date":"2022-06-21","kind":"grant","acquired":true,"shares":2600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction involved the Reporting Person's receipt of a grant of restricted stock units. The restricted stock units vest with respect to 100% of the shares underlying the restricted stock units on the earlier of (i) June 21, 2023 and (ii) the next annual meeting of the Issuer's stockholders. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock."}],"balance_after":13412,"source":{"system":"sec-edgar","filing":"0001415889-22-007131","document":"form4-06302022_060625.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1532475/000141588922007131/form4-06302022_060625.xml","form_type":"4"}},{"id":2221599,"issuer":{"id":110652,"kind":"organization","name":"Aceragen, Inc.","symbol":"ACGN"},"owners":[{"id":77330,"kind":"person","name":"Goldberg Mark Alan","position":1,"cik":"0001532475","reported_name":"Goldberg Mark Alan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-27T16:31:13.000Z","date":"2022-06-23","kind":"grant","acquired":true,"shares":26000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Non-qualified stock options granted, under the Issuer's 2013 Stock Incentive Plan, on the date of the Issuer's 2022 annual meeting of stockholders at an exercise price equal to the closing price of the Issuer's common stock on the date of grant, pursuant to the Issuer's director compensation policy."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vest in full and become immediately exercisable on June 23, 2023 (first anniversary of the date of grant), subject to continued service as a director of the Issuer."}],"balance_after":26000,"derivative":{"exercise_price":0.4561,"exercise_date":"2023-06-23","expiration_date":"2032-06-23","underlying":"Common Stock","underlying_shares":26000},"source":{"system":"sec-edgar","filing":"0001415889-22-006941","document":"form4-06272022_040617.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/861838/000141588922006941/form4-06272022_040617.xml","form_type":"4"}},{"id":2228958,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":77330,"kind":"person","name":"Goldberg Mark Alan","position":1,"cik":"0001532475","reported_name":"Goldberg Mark Alan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-17T16:22:46.000Z","date":"2022-06-15","kind":"grant","acquired":true,"shares":44000,"price":3.37,"value":148280.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Exercisable as to 11,000 shares on each of 9/1/22, 12/1/22, 3/1/23, and 6/1/23, contingent upon the individual remaining a director as of each vesting date."}],"balance_after":44000,"derivative":{"exercise_price":3.37,"expiration_date":"2032-06-15","underlying":"Common Stock","underlying_shares":44000},"source":{"system":"sec-edgar","filing":"0001415889-22-006735","document":"form4-06172022_010658.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/855654/000141588922006735/form4-06172022_010658.xml","form_type":"4"}},{"id":2228957,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":77330,"kind":"person","name":"Goldberg Mark Alan","position":1,"cik":"0001532475","reported_name":"Goldberg Mark Alan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Deferred Share Unit","published_at":"2022-06-17T16:22:46.000Z","date":"2022-06-15","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The deferred share units vest ratably over a one-year period in quarterly increments beginning on 9/1/22, contingent upon the individual remaining a director as of each vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F3","text":"The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors."}],"balance_after":149668,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001415889-22-006735","document":"form4-06172022_010658.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/855654/000141588922006735/form4-06172022_010658.xml","form_type":"4"}},{"id":2261554,"issuer":{"id":5255,"kind":"organization","name":"CRESCENT BIOPHARMA, INC.","symbol":"CBIO"},"owners":[{"id":77330,"kind":"person","name":"Goldberg Mark Alan","position":1,"cik":"0001532475","reported_name":"Goldberg Mark Alan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-05-20T20:08:57.000Z","date":"2022-05-18","kind":"grant","acquired":true,"shares":21000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option vest on May 18, 2023, subject to the reporting person's continuous service as of such vesting date."}],"balance_after":21000,"derivative":{"exercise_price":0.6,"expiration_date":"2032-05-17","underlying":"Common Stock","underlying_shares":21000},"source":{"system":"sec-edgar","filing":"0001209191-22-030977","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1253689/000120919122030977/doc4.xml","form_type":"4"}},{"id":2294280,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":77330,"kind":"person","name":"Goldberg Mark Alan","position":1,"cik":"0001532475","reported_name":"Goldberg Mark Alan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Deferred Share Unit","published_at":"2022-04-20T17:38:30.000Z","date":"2022-03-31","kind":"grant","acquired":true,"shares":3545,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis."},{"field":"shares","element":"transactionShares","label":"F4","text":"Due to clerical error, this amendment to Form 4 is being filed to correct the number of DSUs awarded on March 31, 2022 and the number of DSUs beneficially owned following the reported transaction."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The deferred share units vest upon issuance."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F4","text":"Due to clerical error, this amendment to Form 4 is being filed to correct the number of DSUs awarded on March 31, 2022 and the number of DSUs beneficially owned following the reported transaction."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Due to clerical error, this amendment to Form 4 is being filed to correct the number of DSUs awarded on March 31, 2022 and the number of DSUs beneficially owned following the reported transaction."}],"balance_after":134668,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":3545},"source":{"system":"sec-edgar","filing":"0001179110-22-002691","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/855654/000117911022002691/edgar.xml","form_type":"4/A","original_submission_date":"2022-04-04"}},{"id":2309838,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":77330,"kind":"person","name":"Goldberg Mark Alan","position":1,"cik":"0001532475","reported_name":"Goldberg Mark Alan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Deferred Share Unit","published_at":"2022-04-04T16:11:42.000Z","date":"2022-03-31","kind":"grant","acquired":true,"shares":3151,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The deferred share units vest upon issuance."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors."}],"balance_after":134274,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":3151},"source":{"system":"sec-edgar","filing":"0001179110-22-002534","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/855654/000117911022002534/edgar.xml","form_type":"4"}},{"id":2347215,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":77330,"kind":"person","name":"Goldberg Mark Alan","position":1,"cik":"0001532475","reported_name":"Goldberg Mark Alan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-03-07T16:05:46.000Z","date":"2022-03-03","kind":"purchase","acquired":true,"shares":5000,"price":59.98,"value":299900.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $59.86 to $60.11 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":10812,"source":{"system":"sec-edgar","filing":"0001415889-22-002653","document":"form4-03072022_040307.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1532475/000141588922002653/form4-03072022_040307.xml","form_type":"4"}},{"id":2452168,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":77330,"kind":"person","name":"Goldberg Mark Alan","position":1,"cik":"0001532475","reported_name":"Goldberg Mark Alan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Deferred Share Unit","published_at":"2022-01-04T16:02:30.000Z","date":"2021-12-31","kind":"grant","acquired":true,"shares":1819,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The deferred share units vest upon issuance."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors."}],"balance_after":131123,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":1819},"source":{"system":"sec-edgar","filing":"0001179110-22-000100","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/855654/000117911022000100/edgar.xml","form_type":"4"}},{"id":2555234,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":77330,"kind":"person","name":"Goldberg Mark Alan","position":1,"cik":"0001532475","reported_name":"Goldberg Mark Alan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Deferred Share Unit","published_at":"2021-10-01T16:14:36.000Z","date":"2021-09-30","kind":"grant","acquired":true,"shares":2380,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The deferred share units vest upon issuance."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors."}],"balance_after":129304,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":2380},"source":{"system":"sec-edgar","filing":"0001179110-21-009041","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/855654/000117911021009041/edgar.xml","form_type":"4"}},{"id":2646304,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":77330,"kind":"person","name":"Goldberg Mark Alan","position":1,"cik":"0001532475","reported_name":"Goldberg Mark Alan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Deferred Share Unit","published_at":"2021-07-02T16:22:51.000Z","date":"2021-06-30","kind":"grant","acquired":true,"shares":2048,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The deferred share units vest upon issuance."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors."}],"balance_after":126924,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":2048},"source":{"system":"sec-edgar","filing":"0001179110-21-007319","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/855654/000117911021007319/edgar.xml","form_type":"4"}},{"id":2664981,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":77330,"kind":"person","name":"Goldberg Mark Alan","position":1,"cik":"0001532475","reported_name":"Goldberg Mark Alan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-06-17T16:23:28.000Z","date":"2021-06-16","kind":"grant","acquired":true,"shares":44000,"price":6.77,"value":297880.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Exercisable as to 11,000 shares on each of 9/1/21, 12/1/21, 3/1/22, and 6/1/22, contingent upon the individual remaining a director as of each vesting date."}],"balance_after":44000,"derivative":{"exercise_price":6.77,"expiration_date":"2031-06-16","underlying":"Common Stock","underlying_shares":44000},"source":{"system":"sec-edgar","filing":"0001179110-21-006817","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/855654/000117911021006817/edgar.xml","form_type":"4"}},{"id":2664980,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":77330,"kind":"person","name":"Goldberg Mark Alan","position":1,"cik":"0001532475","reported_name":"Goldberg Mark Alan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Deferred Share Unit","published_at":"2021-06-17T16:23:28.000Z","date":"2021-06-16","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The deferred share units vest quarterly on each of 9/1/21, 12/1/21, 3/1/22, and 6/1/22, contingent upon the individual remaining a director as of each vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors."}],"balance_after":124876,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001179110-21-006817","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/855654/000117911021006817/edgar.xml","form_type":"4"}},{"id":2674656,"issuer":{"id":110652,"kind":"organization","name":"Aceragen, Inc.","symbol":"ACGN"},"owners":[{"id":77330,"kind":"person","name":"Goldberg Mark Alan","position":1,"cik":"0001532475","reported_name":"Goldberg Mark Alan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-10T17:06:02.000Z","date":"2021-06-08","kind":"grant","acquired":true,"shares":26000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Non-qualified stock options granted, under the Issuer's 2013 Stock Incentive Plan, on the date of the Issuer's 2021 annual meeting of stockholders at an exercise price equal to the closing price of the Issuer's common stock on the date of grant, pursuant to the Issuer's director compensation policy."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vest in full and become immediately exercisable on June 8, 2022 (first anniversary of the date of grant), subject to continued service as a director of the Issuer."}],"balance_after":26000,"derivative":{"exercise_price":1.31,"exercise_date":"2022-06-08","expiration_date":"2031-06-08","underlying":"Common Stock","underlying_shares":26000},"source":{"system":"sec-edgar","filing":"0001415889-21-002918","document":"form4-06102021_050633.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/861838/000141588921002918/form4-06102021_050633.xml","form_type":"4"}},{"id":2680504,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":77330,"kind":"person","name":"Goldberg Mark Alan","position":1,"cik":"0001532475","reported_name":"Goldberg Mark Alan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-04T16:21:56.000Z","date":"2021-06-02","kind":"grant","acquired":true,"shares":4500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option vests with respect to 100% of the shares underlying the option on the earlier of (i) the next annual meeting of the Issuer's stockholders and (ii) June 2, 2022."}],"balance_after":4500,"derivative":{"exercise_price":87.13,"expiration_date":"2031-06-02","underlying":"Common Stock","underlying_shares":4500},"source":{"system":"sec-edgar","filing":"0001179110-21-006420","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1532475/000117911021006420/edgar.xml","form_type":"4"}},{"id":2680503,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":77330,"kind":"person","name":"Goldberg Mark Alan","position":1,"cik":"0001532475","reported_name":"Goldberg Mark Alan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-04T16:21:56.000Z","date":"2021-06-02","kind":"grant","acquired":true,"shares":2250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction involved the Reporting Person's receipt of a grant of restricted stock units. The restricted stock units vest with respect to 100% of the shares underlying the restricted stock units on the earlier of (i) the next annual meeting of the Issuer's stockholders and (ii) June 2, 2022. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock."}],"balance_after":5812,"source":{"system":"sec-edgar","filing":"0001179110-21-006420","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1532475/000117911021006420/edgar.xml","form_type":"4"}},{"id":2692870,"issuer":{"id":5255,"kind":"organization","name":"CRESCENT BIOPHARMA, INC.","symbol":"CBIO"},"owners":[{"id":77330,"kind":"person","name":"Goldberg Mark Alan","position":1,"cik":"0001532475","reported_name":"Goldberg Mark Alan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-05-28T00:51:21.000Z","date":"2021-05-18","kind":"grant","acquired":true,"shares":10500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares underlying this option vest on May 18, 2022, subject to the reporting person's continuous service as of such vesting date."}],"balance_after":10500,"derivative":{"exercise_price":2.55,"expiration_date":"2031-05-17","underlying":"Common Stock","underlying_shares":10500},"source":{"system":"sec-edgar","filing":"0001209191-21-036378","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1253689/000120919121036378/doc4.xml","form_type":"4"}},{"id":2692869,"issuer":{"id":5255,"kind":"organization","name":"CRESCENT BIOPHARMA, INC.","symbol":"CBIO"},"owners":[{"id":77330,"kind":"person","name":"Goldberg Mark Alan","position":1,"cik":"0001532475","reported_name":"Goldberg Mark Alan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-05-28T00:51:21.000Z","date":"2021-05-18","kind":"grant","acquired":true,"shares":5250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The security represents restricted stock units granted to the reporting person. Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"shares","element":"transactionShares","label":"F2","text":"The shares underlying these restricted stock units vest on May 18, 2022, subject to the reporting person's continuous service as of such vesting date."}],"balance_after":5250,"source":{"system":"sec-edgar","filing":"0001209191-21-036378","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1253689/000120919121036378/doc4.xml","form_type":"4"}},{"id":2759456,"issuer":{"id":110652,"kind":"organization","name":"Aceragen, Inc.","symbol":"ACGN"},"owners":[{"id":77330,"kind":"person","name":"Goldberg Mark Alan","position":1,"cik":"0001532475","reported_name":"Goldberg Mark Alan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-04-05T16:30:51.000Z","date":"2021-04-01","kind":"grant","acquired":true,"shares":10511,"price":1.32,"value":13874.52,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This stock was issued to the reporting person pursuant to his election, under the Issuer's director compensation program, to receive common stock in lieu of cash fees."}],"balance_after":48610,"source":{"system":"sec-edgar","filing":"0001415889-21-001878","document":"form4-04052021_040417.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/861838/000141588921001878/form4-04052021_040417.xml","form_type":"4"}},{"id":2762676,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":77330,"kind":"person","name":"Goldberg Mark Alan","position":1,"cik":"0001532475","reported_name":"Goldberg Mark Alan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Deferred Share Unit","published_at":"2021-04-02T13:02:12.000Z","date":"2021-03-31","kind":"grant","acquired":true,"shares":1666,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The deferred share units vest upon issuance."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors."}],"balance_after":109876,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":1666},"source":{"system":"sec-edgar","filing":"0001179110-21-004072","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/855654/000117911021004072/edgar.xml","form_type":"4"}},{"id":2917390,"issuer":{"id":110652,"kind":"organization","name":"Aceragen, Inc.","symbol":"ACGN"},"owners":[{"id":77330,"kind":"person","name":"Goldberg Mark Alan","position":1,"cik":"0001532475","reported_name":"Goldberg Mark Alan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-01-06T16:38:35.000Z","date":"2021-01-04","kind":"grant","acquired":true,"shares":3452,"price":4.02,"value":13877.04,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This stock was issued to the reporting person pursuant to his election, under the Issuer's director compensation program, to receive common stock in lieu of cash fees."}],"balance_after":38099,"source":{"system":"sec-edgar","filing":"0001179110-21-000330","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/861838/000117911021000330/edgar.xml","form_type":"4"}},{"id":2926691,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":77330,"kind":"person","name":"Goldberg Mark Alan","position":1,"cik":"0001532475","reported_name":"Goldberg Mark Alan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Deferred Share Unit","published_at":"2021-01-04T10:46:19.000Z","date":"2020-12-31","kind":"grant","acquired":true,"shares":2093,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The deferred share units vest upon issuance."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors."}],"balance_after":108210,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":2093},"source":{"system":"sec-edgar","filing":"0001179110-21-000026","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/855654/000117911021000026/edgar.xml","form_type":"4"}},{"id":2930918,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":77330,"kind":"person","name":"Goldberg Mark Alan","position":1,"cik":"0001532475","reported_name":"Goldberg Mark Alan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-12-28T16:23:13.000Z","date":"2020-12-24","kind":"exercise","acquired":false,"shares":5455,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effected pursuant to a trading plan adopted on August 5, 2020 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option was granted on June 25, 2015 and is fully vested as of the date hereof."}],"balance_after":0,"derivative":{"exercise_price":28.15,"expiration_date":"2025-06-25","underlying":"Common Stock","underlying_shares":5455},"source":{"system":"sec-edgar","filing":"0001179110-20-012241","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1532475/000117911020012241/edgar.xml","form_type":"4"}},{"id":2930917,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":77330,"kind":"person","name":"Goldberg Mark Alan","position":1,"cik":"0001532475","reported_name":"Goldberg Mark Alan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-12-28T16:23:13.000Z","date":"2020-12-24","kind":"sale","acquired":false,"shares":5455,"price":125,"value":681875.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effected pursuant to a trading plan adopted on August 5, 2020 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $125.00 to $125.01 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":3562,"source":{"system":"sec-edgar","filing":"0001179110-20-012241","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1532475/000117911020012241/edgar.xml","form_type":"4"}},{"id":2930916,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":77330,"kind":"person","name":"Goldberg Mark Alan","position":1,"cik":"0001532475","reported_name":"Goldberg Mark Alan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-12-28T16:23:13.000Z","date":"2020-12-24","kind":"exercise","acquired":true,"shares":5455,"price":28.15,"value":153558.25,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effected pursuant to a trading plan adopted on August 5, 2020 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."}],"balance_after":9017,"source":{"system":"sec-edgar","filing":"0001179110-20-012241","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1532475/000117911020012241/edgar.xml","form_type":"4"}},{"id":2934251,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":77330,"kind":"person","name":"Goldberg Mark Alan","position":1,"cik":"0001532475","reported_name":"Goldberg Mark Alan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-12-22T16:14:22.000Z","date":"2020-12-18","kind":"exercise","acquired":false,"shares":5454,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effected pursuant to a trading plan adopted on August 5, 2020 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on June 25, 2015 and is fully vested as of the date hereof."}],"balance_after":5455,"derivative":{"exercise_price":28.15,"expiration_date":"2025-06-25","underlying":"Common Stock","underlying_shares":5454},"source":{"system":"sec-edgar","filing":"0001179110-20-012178","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1532475/000117911020012178/edgar.xml","form_type":"4"}},{"id":2934250,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":77330,"kind":"person","name":"Goldberg Mark Alan","position":1,"cik":"0001532475","reported_name":"Goldberg Mark Alan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-12-22T16:14:22.000Z","date":"2020-12-18","kind":"sale","acquired":false,"shares":5454,"price":120,"value":654480.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effected pursuant to a trading plan adopted on August 5, 2020 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."}],"balance_after":3562,"source":{"system":"sec-edgar","filing":"0001179110-20-012178","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1532475/000117911020012178/edgar.xml","form_type":"4"}},{"id":2934249,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":77330,"kind":"person","name":"Goldberg Mark Alan","position":1,"cik":"0001532475","reported_name":"Goldberg Mark Alan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-12-22T16:14:22.000Z","date":"2020-12-18","kind":"exercise","acquired":true,"shares":5454,"price":28.15,"value":153530.1,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effected pursuant to a trading plan adopted on August 5, 2020 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."}],"balance_after":9016,"source":{"system":"sec-edgar","filing":"0001179110-20-012178","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1532475/000117911020012178/edgar.xml","form_type":"4"}},{"id":2944053,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":77330,"kind":"person","name":"Goldberg Mark Alan","position":1,"cik":"0001532475","reported_name":"Goldberg Mark Alan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-12-15T16:08:31.000Z","date":"2020-12-11","kind":"exercise","acquired":false,"shares":5455,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effected pursuant to a trading plan adopted on August 5, 2020 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on June 25, 2015 and is fully vested as of the date hereof."}],"balance_after":10909,"derivative":{"exercise_price":28.15,"expiration_date":"2025-06-25","underlying":"Common Stock","underlying_shares":5455},"source":{"system":"sec-edgar","filing":"0001179110-20-011906","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1532475/000117911020011906/edgar.xml","form_type":"4"}},{"id":2944052,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":77330,"kind":"person","name":"Goldberg Mark Alan","position":1,"cik":"0001532475","reported_name":"Goldberg Mark Alan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-12-15T16:08:31.000Z","date":"2020-12-11","kind":"sale","acquired":false,"shares":5455,"price":115,"value":627325.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effected pursuant to a trading plan adopted on August 5, 2020 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."}],"balance_after":3562,"source":{"system":"sec-edgar","filing":"0001179110-20-011906","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1532475/000117911020011906/edgar.xml","form_type":"4"}},{"id":2944051,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":77330,"kind":"person","name":"Goldberg Mark Alan","position":1,"cik":"0001532475","reported_name":"Goldberg Mark Alan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-12-15T16:08:31.000Z","date":"2020-12-11","kind":"exercise","acquired":true,"shares":5455,"price":28.15,"value":153558.25,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effected pursuant to a trading plan adopted on August 5, 2020 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."}],"balance_after":9017,"source":{"system":"sec-edgar","filing":"0001179110-20-011906","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1532475/000117911020011906/edgar.xml","form_type":"4"}},{"id":2957738,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":77330,"kind":"person","name":"Goldberg Mark Alan","position":1,"cik":"0001532475","reported_name":"Goldberg Mark Alan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-12-03T16:10:46.000Z","date":"2020-12-01","kind":"exercise","acquired":false,"shares":5454,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effected pursuant to a trading plan adopted on August 5, 2020 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on June 25, 2015 and is fully vested as of the date hereof."}],"balance_after":16364,"derivative":{"exercise_price":28.15,"expiration_date":"2025-06-25","underlying":"Common Stock","underlying_shares":5454},"source":{"system":"sec-edgar","filing":"0001179110-20-011608","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1532475/000117911020011608/edgar.xml","form_type":"4"}},{"id":2957737,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":77330,"kind":"person","name":"Goldberg Mark Alan","position":1,"cik":"0001532475","reported_name":"Goldberg Mark Alan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-12-03T16:10:46.000Z","date":"2020-12-01","kind":"sale","acquired":false,"shares":5454,"price":110,"value":599940.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effected pursuant to a trading plan adopted on August 5, 2020 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."}],"balance_after":3562,"source":{"system":"sec-edgar","filing":"0001179110-20-011608","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1532475/000117911020011608/edgar.xml","form_type":"4"}},{"id":2957736,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":77330,"kind":"person","name":"Goldberg Mark Alan","position":1,"cik":"0001532475","reported_name":"Goldberg Mark Alan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-12-03T16:10:46.000Z","date":"2020-12-01","kind":"exercise","acquired":true,"shares":5454,"price":28.15,"value":153530.1,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effected pursuant to a trading plan adopted on August 5, 2020 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."}],"balance_after":9016,"source":{"system":"sec-edgar","filing":"0001179110-20-011608","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1532475/000117911020011608/edgar.xml","form_type":"4"}},{"id":3001941,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":77330,"kind":"person","name":"Goldberg Mark Alan","position":1,"cik":"0001532475","reported_name":"Goldberg Mark Alan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-10-21T16:21:38.000Z","date":"2020-10-19","kind":"exercise","acquired":false,"shares":5455,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effected pursuant to a trading plan adopted on August 5, 2020 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on June 23, 2016 and is fully vested as of the date hereof."}],"balance_after":0,"derivative":{"exercise_price":19.53,"expiration_date":"2026-06-23","underlying":"Common Stock","underlying_shares":5455},"source":{"system":"sec-edgar","filing":"0001179110-20-010626","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1532475/000117911020010626/edgar.xml","form_type":"4"}},{"id":3001940,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":77330,"kind":"person","name":"Goldberg Mark Alan","position":1,"cik":"0001532475","reported_name":"Goldberg Mark Alan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-10-21T16:21:38.000Z","date":"2020-10-19","kind":"sale","acquired":false,"shares":5455,"price":105,"value":572775.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effected pursuant to a trading plan adopted on August 5, 2020 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."}],"balance_after":3562,"source":{"system":"sec-edgar","filing":"0001179110-20-010626","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1532475/000117911020010626/edgar.xml","form_type":"4"}},{"id":3001939,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":77330,"kind":"person","name":"Goldberg Mark Alan","position":1,"cik":"0001532475","reported_name":"Goldberg Mark Alan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-10-21T16:21:38.000Z","date":"2020-10-19","kind":"exercise","acquired":true,"shares":5455,"price":19.53,"value":106536.15,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effected pursuant to a trading plan adopted on August 5, 2020 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."}],"balance_after":9017,"source":{"system":"sec-edgar","filing":"0001179110-20-010626","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1532475/000117911020010626/edgar.xml","form_type":"4"}},{"id":3009244,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":77330,"kind":"person","name":"Goldberg Mark Alan","position":1,"cik":"0001532475","reported_name":"Goldberg Mark Alan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-10-09T16:04:27.000Z","date":"2020-10-07","kind":"exercise","acquired":false,"shares":5454,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effected pursuant to a trading plan adopted on August 5, 2020 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on June 23, 2016 and is fully vested as of the date hereof."}],"balance_after":5455,"derivative":{"exercise_price":19.53,"expiration_date":"2026-06-23","underlying":"Common Stock","underlying_shares":5454},"source":{"system":"sec-edgar","filing":"0001179110-20-010368","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1532475/000117911020010368/edgar.xml","form_type":"4"}},{"id":3009243,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":77330,"kind":"person","name":"Goldberg Mark Alan","position":1,"cik":"0001532475","reported_name":"Goldberg Mark Alan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-10-09T16:04:27.000Z","date":"2020-10-07","kind":"sale","acquired":false,"shares":5454,"price":100,"value":545400.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effected pursuant to a trading plan adopted on August 5, 2020 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."}],"balance_after":3562,"source":{"system":"sec-edgar","filing":"0001179110-20-010368","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1532475/000117911020010368/edgar.xml","form_type":"4"}},{"id":3009242,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":77330,"kind":"person","name":"Goldberg Mark Alan","position":1,"cik":"0001532475","reported_name":"Goldberg Mark Alan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-10-09T16:04:27.000Z","date":"2020-10-07","kind":"exercise","acquired":true,"shares":5454,"price":19.53,"value":106516.62,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effected pursuant to a trading plan adopted on August 5, 2020 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."}],"balance_after":9016,"source":{"system":"sec-edgar","filing":"0001179110-20-010368","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1532475/000117911020010368/edgar.xml","form_type":"4"}},{"id":3014445,"issuer":{"id":110652,"kind":"organization","name":"Aceragen, Inc.","symbol":"ACGN"},"owners":[{"id":77330,"kind":"person","name":"Goldberg Mark Alan","position":1,"cik":"0001532475","reported_name":"Goldberg Mark Alan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-10-05T16:06:59.000Z","date":"2020-10-01","kind":"grant","acquired":true,"shares":6166,"price":2.25,"value":13873.5,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This stock was issued to the reporting person pursuant to his election, under the Issuer's director compensation program, to receive common stock in lieu of cash fees."}],"balance_after":34647,"source":{"system":"sec-edgar","filing":"0001179110-20-010221","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/861838/000117911020010221/edgar.xml","form_type":"4"}},{"id":3019208,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":77330,"kind":"person","name":"Goldberg Mark Alan","position":1,"cik":"0001532475","reported_name":"Goldberg Mark Alan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Deferred Share Unit","published_at":"2020-10-01T14:39:54.000Z","date":"2020-09-30","kind":"grant","acquired":true,"shares":3750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The deferred share units vest upon issuance."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors."}],"balance_after":106117,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":3750},"source":{"system":"sec-edgar","filing":"0001179110-20-010030","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/855654/000117911020010030/edgar.xml","form_type":"4"}},{"id":3093799,"issuer":{"id":110652,"kind":"organization","name":"Aceragen, Inc.","symbol":"ACGN"},"owners":[{"id":77330,"kind":"person","name":"Goldberg Mark Alan","position":1,"cik":"0001532475","reported_name":"Goldberg Mark Alan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-07-02T20:58:09.000Z","date":"2020-07-01","kind":"grant","acquired":true,"shares":7751,"price":1.79,"value":13874.29,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This stock was issued to the reporting person pursuant to his election, under the Issuer's director compensation program, to receive common stock in lieu of cash fees."}],"balance_after":28481,"source":{"system":"sec-edgar","filing":"0001179110-20-008006","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/861838/000117911020008006/edgar.xml","form_type":"4"}},{"id":3093810,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":77330,"kind":"person","name":"Goldberg Mark Alan","position":1,"cik":"0001532475","reported_name":"Goldberg Mark Alan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Deferred Share Unit","published_at":"2020-07-02T08:34:14.000Z","date":"2020-06-30","kind":"grant","acquired":true,"shares":2934,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The deferred share units vest upon issuance."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors."}],"balance_after":102367,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":2934},"source":{"system":"sec-edgar","filing":"0001179110-20-007815","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/855654/000117911020007815/edgar.xml","form_type":"4"}},{"id":3098278,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":77330,"kind":"person","name":"Goldberg Mark Alan","position":1,"cik":"0001532475","reported_name":"Goldberg Mark Alan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-06-26T16:12:00.000Z","date":"2020-06-24","kind":"grant","acquired":true,"shares":4500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option vests with respect to 100% of the shares underlying the option on the earlier of (i) the next annual meeting of the Issuer's stockholders and (ii) June 24, 2021."}],"balance_after":4500,"derivative":{"exercise_price":76.24,"expiration_date":"2030-06-24","underlying":"Common Stock","underlying_shares":4500},"source":{"system":"sec-edgar","filing":"0001179110-20-007796","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1532475/000117911020007796/edgar.xml","form_type":"4"}},{"id":3098277,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":77330,"kind":"person","name":"Goldberg Mark Alan","position":1,"cik":"0001532475","reported_name":"Goldberg Mark Alan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-06-26T16:12:00.000Z","date":"2020-06-24","kind":"grant","acquired":true,"shares":2250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction involved the Reporting Person's receipt of a grant of restricted stock units. The restricted stock units vest with respect to 100% of the shares underlying the restricted stock units on the earlier of (i) the next annual meeting of the Issuer's stockholders and (ii) June 24, 2021. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock."}],"balance_after":3562,"source":{"system":"sec-edgar","filing":"0001179110-20-007796","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1532475/000117911020007796/edgar.xml","form_type":"4"}},{"id":3101586,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":77330,"kind":"person","name":"Goldberg Mark Alan","position":1,"cik":"0001532475","reported_name":"Goldberg Mark Alan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2020-06-23T16:11:40.000Z","date":"2020-06-19","kind":"exercise","acquired":false,"shares":1312,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On June 19, 2019, the reporting person was granted 1,312 restricted stock units. These restricted stock units are fully vested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On June 19, 2019, the reporting person was granted 1,312 restricted stock units. These restricted stock units are fully vested."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1312},"source":{"system":"sec-edgar","filing":"0001179110-20-007716","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1532475/000117911020007716/edgar.xml","form_type":"4"}},{"id":3101585,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":77330,"kind":"person","name":"Goldberg Mark Alan","position":1,"cik":"0001532475","reported_name":"Goldberg Mark Alan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-06-23T16:11:40.000Z","date":"2020-06-19","kind":"exercise","acquired":true,"shares":1312,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock."}],"balance_after":1312,"source":{"system":"sec-edgar","filing":"0001179110-20-007716","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1532475/000117911020007716/edgar.xml","form_type":"4"}},{"id":3106015,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":77330,"kind":"person","name":"Goldberg Mark Alan","position":1,"cik":"0001532475","reported_name":"Goldberg Mark Alan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-06-18T16:09:17.000Z","date":"2020-06-17","kind":"grant","acquired":true,"shares":50000,"price":4.56,"value":228000.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Exercisable as to 12,500 shares on each of  9/1/20, 12/1/20, 3/1/21 and 6/1/21, contingent upon the individual remaining a director as of each vesting date."}],"balance_after":50000,"derivative":{"exercise_price":4.56,"expiration_date":"2030-06-17","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001179110-20-007533","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/855654/000117911020007533/edgar.xml","form_type":"4"}},{"id":3106014,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":77330,"kind":"person","name":"Goldberg Mark Alan","position":1,"cik":"0001532475","reported_name":"Goldberg Mark Alan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Deferred Share Unit","published_at":"2020-06-18T16:09:17.000Z","date":"2020-06-17","kind":"grant","acquired":true,"shares":17000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The deferred share units vest quarterly on each of 9/1/20, 12/1/20, 3/1/21 and 6/1/21, contingent upon the individual remaining a director as of each vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors."}],"balance_after":99433,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":17000},"source":{"system":"sec-edgar","filing":"0001179110-20-007533","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/855654/000117911020007533/edgar.xml","form_type":"4"}},{"id":3133338,"issuer":{"id":5255,"kind":"organization","name":"CRESCENT BIOPHARMA, INC.","symbol":"CBIO"},"owners":[{"id":77330,"kind":"person","name":"Goldberg Mark Alan","position":1,"cik":"0001532475","reported_name":"Goldberg Mark Alan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-05-27T20:28:42.000Z","date":"2020-05-22","kind":"grant","acquired":true,"shares":21000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option vest on May 22, 2021, subject to the reporting person's continuous service as of such vesting date."}],"balance_after":21000,"derivative":{"exercise_price":3,"expiration_date":"2030-05-21","underlying":"Common Stock","underlying_shares":21000},"source":{"system":"sec-edgar","filing":"0001209191-20-032302","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1253689/000120919120032302/doc4.xml","form_type":"4"}},{"id":3143936,"issuer":{"id":110652,"kind":"organization","name":"Aceragen, Inc.","symbol":"ACGN"},"owners":[{"id":77330,"kind":"person","name":"Goldberg Mark Alan","position":1,"cik":"0001532475","reported_name":"Goldberg Mark Alan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-05-19T19:07:03.000Z","date":"2020-05-12","kind":"grant","acquired":true,"shares":11500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Non-qualified stock options granted, under the Issuer's 2013 Stock Incentive Plan, on the date of the Issuer's 2020 annual meeting of stockholders at an exercise price equal to the closing price of the Issuer's common stock on the date of grant, pursuant to the Issuer's director compensation policy."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vest in full and become immediately exercisable on May 12, 2021 (first anniversary of the date of grant), subject to continued service as a director of the Issuer."}],"balance_after":11500,"derivative":{"exercise_price":1.97,"exercise_date":"2021-05-12","expiration_date":"2030-05-12","underlying":"Common Stock","underlying_shares":11500},"source":{"system":"sec-edgar","filing":"0001179110-20-006348","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/861838/000117911020006348/edgar.xml","form_type":"4"}},{"id":3184892,"issuer":{"id":110652,"kind":"organization","name":"Aceragen, Inc.","symbol":"ACGN"},"owners":[{"id":77330,"kind":"person","name":"Goldberg Mark Alan","position":1,"cik":"0001532475","reported_name":"Goldberg Mark Alan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-04-03T17:19:09.000Z","date":"2020-04-01","kind":"grant","acquired":true,"shares":10730,"price":1.28,"value":13734.4,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This stock was issued to the reporting person pursuant to his election, under the Issuer's director compensation program, to receive common stock in lieu of cash fees."}],"balance_after":20730,"source":{"system":"sec-edgar","filing":"0001179110-20-004665","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/861838/000117911020004665/edgar.xml","form_type":"4"}},{"id":3187786,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":77330,"kind":"person","name":"Goldberg Mark Alan","position":1,"cik":"0001532475","reported_name":"Goldberg Mark Alan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Deferred Share Unit","published_at":"2020-04-02T07:51:07.000Z","date":"2020-03-31","kind":"grant","acquired":true,"shares":3958,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The deferred share units vest upon issuance."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors."}],"balance_after":82433,"derivative":{"exercise_price":0,"exercise_date":"2020-03-31","underlying":"Common Stock","underlying_shares":3958},"source":{"system":"sec-edgar","filing":"0001179110-20-004404","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/855654/000117911020004404/edgar.xml","form_type":"4"}}],"next_cursor":"2020-04-02T07:51:07.000000Z,3187786"}